Published in Drug Law Weekly, July 15th, 2008
"Thus, we pretreated rats with opioid mu(1) (naloxonazine) and kappa (MR2266) or 5-HT1A (NAN-190), 5-HT2 (ketanserin), and 5-HT3 (ondansetron) receptor antagonists. We investigated the possible changes in 5-hydroxyindoleacetic acid/serotonin ratio in the frontal cortex and pons. The antinociceptive effect of AM404 (10 mg/kg,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly